Related by context. All words. (Click for frequent words.) 77 randomisation 67 randomized 60 n = 59 prespecified 59 dose escalation 58 randomizing 58 virologic failure 58 Randomized 57 evaluable 57 unblinded 57 randomize 57 nonrandomized 56 mcg kg 56 evaluable patients 55 postoperatively 55 timepoint 55 prospectively defined 55 placebo 55 dose titration 55 blind placebo 55 mg kg dose 55 undetectable HCV RNA 55 blinded randomized 55 adalimumab 55 dosing 54 randomized #:# 54 dosing cohorts 54 non inferiority 54 coronary revascularization 54 postintervention 54 dosage regimens 54 infliximab 54 secondary endpoint 54 primary efficacy endpoint 54 SVR# 54 randomized blinded 54 eptifibatide 54 timepoints 54 multicenter randomized placebo controlled 53 DAPT 53 preoperative chemotherapy 53 MADIT II 53 HIV RNA 53 atazanavir ritonavir 53 undetectable HBV DNA 53 anticoagulation 53 secondary efficacy endpoints 53 Kaplan Meier estimate 53 secondary efficacy endpoint 53 multicenter randomized 53 posttreatment 53 fibrinolytic therapy 53 Kaplan Meier analysis 53 virologic response 53 primary endpoint 53 noninferiority 53 ancrod 53 #mg/m# [001] 53 revascularization 53 ipsilateral stroke 52 clopidogrel 52 reinfarction 52 virological response 52 rt PA 52 neoadjuvant chemotherapy 52 mg QD 52 sirolimus eluting stents 52 HCV RNA 52 TAXUS Stent 52 rFVIIa 52 nephrectomy 52 randomized crossover 52 prospectively stratified 52 placebo controlled 52 prospective multicenter 52 DLTs 52 insulin detemir 52 trials RCTs 52 HSCT 52 4mg/kg 52 randomized multicenter 52 progression TTP 52 administered subcutaneously 52 titration 52 randomized #:#:# 52 multicenter randomized controlled 52 endpoints 52 CABG 52 #mg QD [001] 52 DMARD 52 mg dose 52 liver metastases 52 #:# randomization 52 warfarin therapy 52 inhaled tobramycin 52 certolizumab 52 blinded placebo 52 composite endpoint 52 #mg/m# [002] 52 prospective randomized 51 unfractionated heparin 51 predefined criteria 51 neoadjuvant 51 APTIVUS r 51 biochemical relapse 51 CR nPR 51 lymphadenectomy 51 label dose titration 51 periprocedural 51 patients evaluable 51 PREZISTA r 51 #mg QD [002] 51 antiretroviral naive 51 postdischarge 51 bolus dose 51 biochemical recurrence 51 multicentre randomized 51 desvenlafaxine succinate 51 p = 51 prospective randomized multicenter 51 angiographic 51 dosing interval 51 postop 51 disease progression 51 posttransplant 51 subanalysis 51 virologic breakthrough 51 peginterferon 51 subgroup analyzes 51 GnRH agonist 51 FOLFOX4 51 intravenous tPA 51 ICD implantation 51 renal function 51 Thrombolysis 51 mitoxantrone 51 multicentre 51 Randomized controlled 51 Free Survival PFS 51 fluorouracil 51 alteplase 51 thrombolytic therapy 51 genotypic resistance 51 mg kg 51 EURIDIS 51 reintervention 51 androgen suppression 51 nonfatal MI 50 evaluable subjects 50 meta regression 50 Butrans 50 Dose escalation 50 androgen deprivation 50 Kaplan Meier curves 50 dose escalation phase 50 virological failure 50 unblinding 50 prospective randomized placebo 50 pharmacokinetics PK 50 mg/m2/day 50 intravitreal injection 50 ribavirin RBV 50 intermittent dosing 50 mg m 50 tumor progression TTP 50 EVEREST II 50 prespecified secondary 50 RRMS patients 50 mg/m2 dose 50 beta blocker therapy 50 Phase IIIb 50 endpoint 50 mg/m2 50 Elitek 50 concurrent chemoradiation 50 RE LY 50 irbesartan 50 GAMMAGARD 50 divalproex sodium 50 docetaxel pretreated 50 ascending dose 50 LPV r 50 mg BID 50 covariate 50 EmbraceAC 50 pegylated interferon alfa 2b 50 paclitaxel eluting stents 50 sirolimus eluting stent 50 VT VF 50 saline placebo 50 nab paclitaxel 50 Kaplan Meier 50 doxorubicin docetaxel 50 rotigotine 50 hepatectomy 50 Secondary endpoints 50 abciximab 50 primary percutaneous coronary 50 mg administered orally 50 tapentadol ER 50 QTc prolongation 50 postoperative 50 NEVO RES 50 XIENCE V PROMUS Stent 50 clevidipine 50 PEG IFN 50 radical cystectomy 50 antibiotic prophylaxis 50 fondaparinux 50 efficacy endpoints 50 goserelin 50 OPCAB 50 preoperative 49 plasma uric acid 49 active comparator 49 tamoxifen therapy 49 plasma HCV RNA 49 randomized clinical 49 neurologic progression 49 Kaplan Meier survival 49 nonfatal myocardial infarction 49 bolus injection 49 otamixaban 49 serum phosphorus 49 SYMMETRY trial 49 P = .# 49 Phase III randomized 49 Secondary endpoints included 49 intraperitoneal 49 FOLFOX 49 everolimus eluting stents 49 EMPHASIS HF trial 49 pharmacokinetic PK 49 BRIM2 49 recurrent GBM 49 double blinded randomized 49 Neuropsychiatric Inventory NPI 49 SIMPADICO 49 concomitant medications 49 diameter stenosis 49 viral kinetic 49 FEV1 49 Acute Coronary Syndromes ACS 49 paroxysmal AF 49 liver biopsies 49 ritonavir boosted lopinavir 49 controlled multicenter 49 low dose cytarabine 49 GOUT 49 viral kinetics 49 F FDG PET 49 sirolimus 49 decitabine 49 cystectomy 49 dexmedetomidine 49 elective PCI 49 secondary endpoints 49 bosentan 49 undergoing coronary angiography 49 anticoagulation therapy 49 crizotinib PF # 49 Polyp Prevention Trial 49 free survival PFS 49 NATRECOR ® 49 Randomised 49 placebo controlled randomized 49 p = #.# [002] 49 factorial 49 sirolimus stent 49 titration phase 49 AMOR IPAT 49 IELT 49 postmenopausal osteoporotic women 49 lipid lowering therapy 49 surrogate endpoint 49 Solid Tumors RECIST 49 prospective nonrandomized 49 vinorelbine 49 placebo controlled dose escalation 49 MS DRG 49 thromboembolic 49 etanercept 49 Secondary endpoints include 49 randomized placebo controlled 49 FOLFIRI 49 antihypertensive therapy 49 TURBT 49 elotuzumab 49 R# #mg BID 49 RCTs 49 target vessel revascularization 49 methotrexate monotherapy 49 efficacy endpoint 49 thrombotic complications 49 SYNTAX trial 48 relapsed MM 48 intravesical 48 RECIST criteria 48 TDF FTC 48 sunitinib 48 confidence interval CI 48 IPSS 48 STRIDE PD 48 dose limiting toxicities 48 vicriviroc 48 FOLPI 48 tipranavir ritonavir 48 Median progression 48 antithrombotic therapy 48 lopinavir r 48 angiographic outcomes 48 nadroparin 48 mITT population 48 dual antiplatelet therapy 48 double blinded placebo 48 elagolix 48 Endpoints 48 mcg albinterferon alfa 2b 48 darunavir ritonavir 48 multicenter prospective 48 external beam radiotherapy 48 LVSD 48 deferoxamine 48 randomized double 48 liver transplant recipients 48 nonresponders 48 antiangiogenic therapy 48 OADs 48 mCi kg 48 unfractionated heparin UFH 48 discontinuations 48 dose dose escalation 48 sustained virological response 48 tumor shrinkage 48 peg interferon 48 chemoradiation therapy 48 placebo controlled clinical 48 oral antidiabetes drugs 48 intravenous diuretics 48 CIMZIA TM certolizumab pegol 48 randomized placebo 48 epoetin alfa 48 detectable HCV RNA 48 randomized controlled 48 MIST II 48 perioperative complications 48 dacarbazine 48 #mg/day [001] 48 postprocedure 48 nonoperative 48 Pharmacokinetic 48 octreotide LAR 48 randomized controlled trials RCTs 48 pneumonectomy 48 CIMZIA TM 48 locoregional recurrence 48 Randomized Evaluation 48 LVEF 48 pharmacodynamics PD 48 Q2W 48 IV NSCLC 48 DMARD therapy 48 QTc 48 PREZISTA ritonavir 48 metastatic RCC 48 left ventricular dysfunction 48 #mg BID [001] 48 TACE 48 Patency 48 randomized multicentre 48 primary endpoints 48 β blockers 48 NSTE ACS 48 achieved statistical significance 48 hepatic resection 48 radical nephrectomy 48 EBRT 48 efavirenz EFV 48 NCT# ClinicalTrials.gov 48 cisplatin vinorelbine 48 gout flares 48 dose cohorts 48 IV bolus 48 postoperative radiotherapy 48 docetaxel 48 peginterferon alfa 2b 48 NIHSS score 48 recurrent glioblastoma multiforme 48 BCIRG 48 XIENCE V demonstrated 48 mL kg 48 QRS duration 48 VELCADE melphalan 48 glulisine 48 thalidomide dexamethasone 48 flutamide 48 efficacy evaluable 48 virologic 48 oral anticoagulation 48 phase IIb 48 post hoc 48 preintervention 48 adefovir 48 dosing cohort 48 abacavir lamivudine 48 QTcF 48 oral rivaroxaban 48 null responder HCV 48 AGGRASTAT R 48 HCV RESPOND 2 48 definite stent thrombosis 48 antimicrobial prophylaxis 48 nucleoside naive patients 48 mcg BID 48 adjuvant trastuzumab 48 Subgroup analysis 48 debulking surgery 47 ATACAND 47 rapid virologic response 47 placebo controlled trials 47 NATRECOR R 47 plus ribavirin 47 noninferior 47 dosing schedules 47 Secondary efficacy endpoints 47 lispro 47 lanthanum carbonate 47 paroxysmal atrial fibrillation 47 stage IIIB 47 ischemic cardiomyopathy 47 TAXUS 47 subcutaneously administered 47 NEVO 47 antiarrhythmic drug 47 QTc intervals 47 platelet reactivity 47 postoperative chemotherapy 47 pretransplant 47 solifenacin 47 GIK infusion 47 tirofiban 47 univariate analysis 47 placebo controlled clinical trials 47 mg clopidogrel 47 Primary endpoints 47 p = #.# [003] 47 docetaxel prednisone 47 q#h 47 MADRS score 47 tolvaptan 47 reperfusion therapy 47 perioperatively 47 nicardipine 47 postoperative complication 47 eplerenone 47 monotherapy 47 TMC# C# 47 seroconversion 47 clodronate 47 ADHF 47 zolmitriptan 47 teriflunomide 47 PASI scores 47 multicenter Phase 47 spontaneous bowel movements 47 acute STEMI 47 Percutaneous Coronary Intervention 47 resynchronization therapy 47 dose regimens 47 L thyroxine 47 HBV DNA 47 BYSTOLIC 47 GP IIb IIIa inhibitor 47 titrated 47 sustained virologic response 47 revascularization procedures 47 clinical pharmacology studies 47 target lesion revascularization 47 prospective randomized controlled 47 avosentan 47 PRECiSE 47 echocardiographic 47 Phase IIB 47 Efficacy 47 XELOX 47 logistic regression analysis 47 periprocedural MI 47 olmesartan 47 AGILECT R 47 binary restenosis 47 PREVENT IV 47 DSMB recommended 47 Phase #/#a 47 epoetin alpha 47 Index CDAI 47 factorial design 47 interquartile range 47 pharmacokinetic pharmacodynamic 47 #mg/day [002] 47 symptomatic VTE 47 label multicenter 47 tinzaparin 47 TEAEs 47 Major Adverse Cardiac 47 antiretroviral regimen 47 blind multicentre 47 phase IIb clinical 47 posaconazole 47 interferon beta 1b 47 DSMB 47 TAXUS Express Stent 47 HCV SPRINT 47 tacrolimus 47 Betaferon ® 47 tenecteplase 47 imatinib therapy 47 thromboembolic events 47 statistically significant improvement 47 MACCE 47 Target Lesion Revascularization TLR 47 Median PFS 47 carboplatin paclitaxel 47 prospective multicenter randomized 47 median PFS 47 axillary node dissection 47 crossclamp 47 ACTIVE W 47 clinical trial 47 telaprevir dosing 47 TRITON TIMI 47 dosing intervals 47 glatiramer acetate 47 transurethral resection 47 BEACOPP 47 transfemoral 47 mcg QD 47 HbA1c levels 47 peg IFN 47 CD4 + cell 47 Kaplan Meier method 47 bevacizumab 47 Kaplan Meier estimates 47 HAM D# 47 BENICAR 47 clopidogrel therapy 47 SAEs 47 Score IPSS 47 Dacogen injection 47 HORIZONS AMI trial 47 PEARL SC 47 lacosamide 47 randomly assigned 47 oblimersen 47 CUSTOM III 47 mapatumumab 47 randomized multicenter trial 47 μg dose 47 pegylated liposomal doxorubicin 47 IIIa inhibitor 47 Phase 2b study 47 vandetanib 47 msec 47 conditional logistic regression 47 pharmacodynamics 47 GSK# [001] 47 % CI #.#-#.# [003] 47 CHAMPION PLATFORM 47 disease progression TTP 47 nonoperative treatment 47 Peg IFN 47 aromatase inhibitor therapy 47 severe neutropenia 47 ventricular fibrillation VF 47 ziprasidone 47 BENICAR HCT 47 prospective multicentre 47 multicentre prospective 47 BoNTA 47 STEMI patients 47 g dL 47 intraoperative 47 randomized controlled trial 47 adjuvant radiotherapy 47 ibandronate 47 Cardiopulmonary bypass 47 RE LY ® 47 anticoagulant therapy 47 SCIg 47 covariates 47 TAXUS ATLAS 47 continuous intravenous infusion 47 total knee arthroplasty 47 IQR 47 hemodialysis patients 47 pegnivacogin 47 blind randomized 47 radiotherapy RT 47 p = NS 47 methotrexate therapy 47 statistically significant differences 46 mg/# hr 46 estimated GFR 46 VADT 46 nonsignificant 46 Pred Forte 46 VAPRISOL 46 sirolimus eluting 46 multicenter randomized double 46 standard chemotherapy regimen 46 BRIM3 46 TNF inhibitor 46 serum creatinine 46 phase IIIb 46 Subgroup analyzes 46 copies mL 46 randomized Phase 2b 46 events AEs 46 cangrelor 46 immunosuppressive regimen 46 multivariate Cox 46 pericardial effusion 46 univariate 46 ENDEAVOR IV 46 mRCC 46 randomized clinical trials 46 Phase III randomized controlled 46 ICD therapy 46 SCr 46 revascularizations 46 glufosfamide 46 ribavirin therapy 46 adefovir treated 46 fibrinolytic 46 prospective observational 46 multivariable adjustment 46 randomising 46 adjuvant tamoxifen 46 EDSS scores 46 letrozole 46 randomized Phase III 46 thienopyridine 46 Pegasys plus Copegus 46 ug dose 46 dose cohort 46 refractory NSCLC 46 empiric 46 pretreatment baseline 46 rHuEPO 46 recurrent ischemia 46 thromboprophylaxis 46 esophagectomy 46 stepwise logistic regression 46 MitraClip device 46 hemorrhagic complications 46 pegylated interferon 46 postoperative AF 46 QD dosing 46 Decompensated Heart Failure 46 Flu Cy 46 multivariate analysis 46 MELD scores 46 treatment naive genotype 46 randomise 46 ABSORB trial 46 PRADAXA 46 MIRAPEX 46 8mg/kg 46 peginterferon alfa 2a 46 MGd 46 pharmacodynamic PD 46 Acute Ischemic Stroke 46 dose escalation Phase 46 specified primary endpoint 46 catheter insertion 46 PreCISe study 46 abatacept 46 comparator PI r 46 graft dysfunction 46 RE LY trial 46 biliary tract cancer 46 plasma pharmacokinetics 46 intraocular inflammation 46 multivariable analysis 46 MIRCERA 46 baseline HbA1c 46 bupivacaine 46 drug eluting stent implantation 46 CIMZIA R 46 citalopram 46 LEXIVA r 46 remission CR 46 phase IIa 46 transcatheter closure 46 enfuvirtide 46 repeat revascularization 46 ug kg 46 Tumor Response 46 KRAS mutations occur 46 multicenter 46 BARI 2D 46 partial remissions 46 everolimus eluting stent 46 lopinavir r arm 46 carotid artery stenting 46 pimecrolimus 46 ALGRX 46 nelfinavir 46 cerebral vasospasm 46 multidose 46 relapsing multiple sclerosis 46 radiographic progression 46 serum HCV RNA 46 platelet inhibitor 46 corrected QT interval 46 lamivudine refractory patients 46 angiographic restenosis 46 topotecan 46 randomizing patients 46 ULN 46 plasma glucose 46 MDRD 46 primary patency 46 sinus rhythm 46 undetectable viral load 46 chemoradiotherapy 46 docetaxel chemotherapy 46 revascularization procedure 46 liver resection 46 palonosetron 46 IFN alfa 46 postvaccination 46 zonisamide SR 46 recanalization 46 mg d 46 comorbidities 46 retinal thickness 46 PEGPH# 46 pharmacokinetic PK study 46 EDARBI 46 TIMI 46 Xelox 46 demonstrated statistically significant 46 chemotherapy regimen 46 multicenter multinational 46 infusional 46 Traficet EN 46 eGFR 46 epoprostenol 46 oral corticosteroids 46 multivariate analyzes 46 cilostazol 46 DES implantation 46 iodixanol 46 Sustained Virological Response 46 postdose 46 statistical significance 46 zotarolimus eluting stent 46 weekly subcutaneous injections 46 HCV genotype 46 ADAS cog 46 eszopiclone 46 tipranavir r 46 adenotonsillectomy 46 nodular partial response 46 dose escalation study 46 Hypotension 46 randomized trials 46 dosing regimens 46 Durezol 46 incontinence episodes 46 CANCIDAS 46 % CI #.#-#.# [007] 46 AEs 46 velafermin 46 gadobutrol 46 #mg BID [002] 46 oral allopurinol 46 FOLFIRI alone 46 glycoprotein IIb IIIa inhibitors 46 bivalirudin 46 chemoradiation 46 etoposide 46 RAPAFLO R 46 atheroma volume 46 reoperation 46 prospective multicenter study 46 virologic response EVR 46 GP IIb IIIa 46 L PPDS 46 PLCO 46 logistic regression model 46 ALT flares 46 mg/m2 cohort 46 curative resection 46 ENDEAVOR III 46 morphometric vertebral fractures 46 comparator 46 subcutaneous SC 46 hepatic arterial 46 postoperative mortality 46 assessing T DM1 46 metastatic malignant melanoma 46 hematologic toxicity 46 clinically meaningful improvement 46 mcg dose 46 Val HeFT 46 endoscopic gastric ulcers 46 oral methylnaltrexone 46 APTIVUS 46 antidepressant therapy 46 coadministration 46 BR.# 46 hypofractionated 46 mesilate 46 melphalan prednisone 46 chlorambucil 46 temsirolimus 46 Naive Patients 46 bisoprolol 46 pharmacodynamic effects 46 NLX P# 46 modified REGENESIS Phase IIb 46 logistic regression models 46 IFN α 46 mesalamine granules 46 deferasirox 46 CSBM 46 LCP Tacro TM 46 multicenter Phase III 46 locoregional disease 46 DCCT 46 blind randomized placebo 46 intravenous IV infusion 46 tolerated dose MTD 46 hours postdose 46 piperacillin tazobactam 46 intradermal injections 46 Phase III VISTA 46 glycoprotein IIb IIIa inhibitor 46 histologic 46 lung metastases 46 ST elevation myocardial 46 imetelstat 46 PSA nadir 46 cerebrovascular events 46 LCP AtorFen 46 5mg/kg 46 TMC# [001] 46 antiretroviral naïve 46 COPD exacerbations 46 Carotid Revascularization Endarterectomy vs. 46 mg subcutaneously 46 prospectively randomized 45 tecarfarin 45 FDA defined valvulopathy 45 multicenter clinical 45 MEND CABG II 45 MERLIN TIMI 45 HGS ETR1 45 creatinine clearance 45 Neovascular AMD 45 PegIFN RBV 45 CAMMS# 45 octreotide 45 pharmacodynamic 45 remission induction 45 CLARITY study 45 prognostic variables 45 autologous SCT 45 induction regimen 45 Multicenter 45 biventricular repair 45 ENDEAVOR II 45 metastatic renal cell carcinoma 45 febrile neutropenia 45 tacrolimus ointment 45 AZILECT R 45 renal dysfunction 45 Welchol 45 sternal wound infections 45 trastuzumab 45 enoxaparin 45 intratumoral 45 bortezomib 45 pegaptanib 45 Phase Ib study 45 ROCKET AF 45 systemic corticosteroids 45 Crohn Disease Activity 45 dose cytarabine 45 TLUS 45 multivariable 45 orBec 45 Response Evaluation Criteria 45 nonmetastatic prostate cancer 45 salmeterol fluticasone 45 clinically relevant 45 Hb A1C 45 urodynamic 45 segment binary restenosis 45 myocardial infarction MI 45 Edge STudy 45 maximal dose 45 % CI #.#-#.# [006] 45 recurrent VTE 45 paclitaxel poliglumex 45 darunavir r 45 oxaliplatin Eloxatin 45 Solid Tumors 45 intravitreal injections 45 cART 45 rHuPH# 45 Aptivus ® 45 receiving VICTRELIS 45 multicenter Phase II 45 dyssynchrony 45 pamidronate 45 intravenous dosing 45 CIMZIA ™ 45 stent binary restenosis 45 inflammatory lesions 45 tenofovir emtricitabine 45 5-FU/LV 45 Proellex TM 45 angiographically 45 histologically proven 45 neo adjuvant 45 KRAS status 45 idarubicin 45 SUVmax 45 NEVO ™ 45 eculizumab therapy 45 nulliparous women 45 ADVANCE PD 45 CRp 45 achieved PASI 45 peak plasma concentrations 45 femoral neck fracture 45 #mg/kg [002] 45 remifentanil 45 bowel resection 45 adjuvant therapy 45 visceral metastases 45 TAXUS V 45 hepatic function 45 RESIST studies 45 hypocalcemia 45 trastuzumab Herceptin ® 45 ECASS 45 LNG IUS 45 Taxus Stent 45 adjuvant chemotherapy 45 placebo dexamethasone 45 viral suppression 45 placebo controlled Phase 45 Monotherapy 45 antiepileptic drug 45 liver metastasis 45 dose proportionality 45 intravenous doses 45 mCRC patients 45 plus dexamethasone 45 Phase 1b clinical 45 NNT = 45 RSD# oral 45 fulvestrant 45 p = #.# [004] 45 Phase 1a clinical 45 PRoFESS 45 tamsulosin 45 RECIST 45 gemcitabine Gemzar ® 45 nondiabetic patients 45 oral prednisone 45 RECIST Response Evaluation Criteria 45 Aflibercept 45 MYLOTARG 45 Pivotal Trial 45 nadolol 45 bisphosphonate therapy 45 cobicistat 45 aripiprazole 45 prior chemotherapy regimens 45 coronary intervention 45 endoscopic remission 45 amisulpride 45 LAB GHRH 45 MVax R 45 KAPIDEX 45 INVEGA SUSTENNA 45 Visual Analogue Scale VAS 45 #Gy 45 rituximab 45 intravenous bolus 45 Prograf ® 45 lymph node dissection 45 CHAMPION PCI 45 ANOVA 45 thrombocytopenic